Neurocrine's new awareness campaign for CAH includes similarly themed patient and physician websites (courtesy Neurocrine)
Neurocrine launches CAH rare disease education campaign ahead of FDA submission
Neurocrine Biosciences’ newly-debuted campaign acknowledges the frustration that congenital adrenal hyperplasia (CAH) patients, families and endocrinologists often feel.
The “What the C@H?!” theme is a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
